Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) insider Gopi Shankar bought 5,000 shares of the business’s stock in a transaction dated Wednesday, November 11th. The stock was purchased at an average price of $2.71 per share, with a total value of $13,550.00. Following the purchase, the insider directly owned 81,443 shares of the company’s stock, valued at $220,710.53. The trade was a 6.54% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Larimar Therapeutics Price Performance
Shares of LRMR traded up $0.32 on Friday, hitting $3.02. The company’s stock had a trading volume of 2,531,459 shares, compared to its average volume of 1,257,255. The company has a market capitalization of $313.72 million, a PE ratio of -1.55 and a beta of 0.73. Larimar Therapeutics, Inc. has a fifty-two week low of $1.91 and a fifty-two week high of $6.42. The company has a 50 day moving average price of $2.93 and a 200 day moving average price of $3.76.
Wall Street Analyst Weigh In
A number of equities analysts have commented on the company. Wall Street Zen lowered Larimar Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Wedbush restated an “outperform” rating on shares of Larimar Therapeutics in a report on Tuesday, November 10th. Leerink Partners initiated coverage on Larimar Therapeutics in a research note on Monday, September 14th. They issued an “outperform” rating and a $13.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Larimar Therapeutics in a report on Thursday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Larimar Therapeutics presently has a consensus rating of “Buy” and an average price target of $10.33.
Check Out Our Latest Analysis on LRMR
Hedge Funds Weigh In On Larimar Therapeutics
Large investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in Larimar Therapeutics during the 2nd quarter worth $17,318,000. AIGH Capital Management LLC bought a new position in Larimar Therapeutics in the 3rd quarter valued at $5,911,000. Dimensional Fund Advisors LP boosted its position in Larimar Therapeutics by 143.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 798,462 shares of the company’s stock valued at $3,592,000 after buying an additional 470,968 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Larimar Therapeutics by 148.9% in the 1st quarter. Renaissance Technologies LLC now owns 739,942 shares of the company’s stock valued at $3,330,000 after buying an additional 442,676 shares during the period. Finally, Hennion & Walsh Asset Management Inc. acquired a new stake in shares of Larimar Therapeutics in the 2nd quarter valued at $1,210,000. 91.92% of the stock is currently owned by institutional investors and hedge funds.
Key Stories Impacting Larimar Therapeutics
These are some of the LRMR stories that stood out recently:
- Positive Sentiment: CEO Carole Ben-Maimon, CFO Michael Celano, COO John B. Jr. Harlow, insider Gopi Shankar, and directors Frank Thomas and Joseph Truitt together purchased 52,810 shares for roughly $195,000. Director Thomas Hamilton separately bought 70,000 shares for $186,900. Insider purchase report Hamilton SEC filing
- Neutral Sentiment: The supplied coverage also notes H.C. Wainwright maintained a Buy rating; no rating change or fresh price-moving catalyst was reported. Analyst rating report
About Larimar Therapeutics
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.
Featured Articles
- Five stocks we like better than Larimar Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
